The influence of AT1002 on the nasal absorption of molecular weight markers and therapeutic agents when co-administered with bioadhesive polymers and an AT1002 antagonist, AT1001

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 1, 2012, Pages 30-39

  Song, Keon Hyoung ^a,b   Eddington, Natalie D ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Seoul National University   (South Korea)

Author keywords

AT1001; AT1002; carrageenan; Na CMC

Indexed keywords

AT 1002; CALCITONIN; INULIN; LARAZOTIDE; MOLECULAR MARKER; PENETRATION ENHANCING AGENT; POLYMER; PROTEINASE ACTIVATED RECEPTOR 2; RECEPTOR PROTEIN; SAQUINAVIR; UNCLASSIFIED DRUG; ZONULIN RECEPTOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; RAT; RECEPTOR BINDING;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALCITONIN; CARBOXYMETHYLCELLULOSE SODIUM; CARRAGEENAN; CHOLERA TOXIN; DRUG COMBINATIONS; INULIN; MALE; MODELS, ANIMAL; MOLECULAR WEIGHT; NASAL MUCOSA; OLIGOPEPTIDES; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY; SAQUINAVIR; TIGHT JUNCTIONS;

EID: 83555160922     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01381.x     Document Type: Article

References (42)

1. Andras IE, et al,. HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 2003; 74: 255-265. (Pubitemid 37193712)
2. Johnson PH, Quay SC,. Advances in nasal drug delivery through tight junction technology. Expert Opin Drug Deliv 2005; 2: 281-298. (Pubitemid 41130883)
3. Larson J, et al,. Endothelial EphA receptor stimulation increases lung vascular permeability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L431-L439.
4. Cox DS, et al,. Enhancing the permeation of marker compounds and enaminone anticonvulsants across Caco-2 monolayers by modulating tight junctions using zonula occludens toxin. Eur J Pharm Biopharm 2001; 52: 145-150. (Pubitemid 32755892)
5. Cox DS, et al,. Enhanced permeability of molecular weight markers and poorly bioavailable compounds across Caco-2 cell monolayers using the absorption enhancer, zonula occludens toxin. Pharm Res 2002; 19: 1680-1688. (Pubitemid 35305520)
6. Karyekar CS, et al,. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci 2003; 92: 414-423. (Pubitemid 36169314)
7. Di Pierro M, et al,. Zonula occludens toxin structure-function analysis. Identification of the fragment biologically active on tight junctions and of the zonulin receptor binding domain. J Biol Chem 2001; 276: 19160-19165.
8. Salama NN, et al,. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol. Int J Pharm 2003; 251: 113-121. (Pubitemid 36071466)
9. Salama NN, et al,. The effect of delta G on the transport and oral absorption of macromolecules. J Pharm Sci 2004; 93: 1310-1319. (Pubitemid 38529704)
10. Salama NN, et al,. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents. J Pharmacol Exp Ther 2005; 312: 199-205. (Pubitemid 40096469)
11. Song KH, et al,. Effect of the six-mer synthetic peptide (AT1002) fragment of zonula occludens toxin on the intestinal absorption of cyclosporin A. Int J Pharm 2008; 351: 8-14.
12. Song KH, et al,. Enhanced nasal absorption of hydrophilic markers after dosing with AT1002, a tight junction modulator. Eur J Pharm Biopharm 2008; 69: 231-237.
13. Gopalakrishnan S, et al,. Mechanism of action of Zot-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm 2009; 365: 121-130.
14. Fasano A, et al,. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA 1991; 88: 5242-5246. (Pubitemid 21914720)
15. Fasano A, et al,. Zonula occludens toxin modulates tight junctions through protein kinase C-dependent actin reorganization, in vitro. J Clin Invest 1995; 96: 710-720.
16. Fasano A, et al,. The enterotoxic effect of zonula occludens toxin on rabbit small intestine involves the paracellular pathway. Gastroenterology 1997; 112: 839-846. (Pubitemid 27113809)
17. Fasano A, Uzzau S,. Modulation of intestinal tight junctions by zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J Clin Invest 1997; 99: 1158-1164. (Pubitemid 27142750)
18. Camerer E, et al,. Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa. Proc Natl Acad Sci USA 2000; 97: 5255-5260. (Pubitemid 30313705)
19. Kawabata A, et al,. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. Br J Pharmacol 2005; 144: 212-219. (Pubitemid 40216119)
20. Fasano A, et al,. P0517 Zot/Zonulin-mediated regulation of intestinal tight junctions involves the proteinase-activated receptor 2 (Par-2). J Pediatr Gastroenterol Nutr 2004; 39: S253-S254.
21. Tripathi A, et al,. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA 2009; 106: 16799-16804.
22. Cenac N, et al,. PAR2 activation alters colonic paracellular permeability in mice via IFNgamma-dependent and -independent pathways. J Physiol 2004; 558 (Pt.3): 913-925. (Pubitemid 39199112)
23. Schipper NG, et al,. The nasal mucociliary clearance: relevance to nasal drug delivery. Pharm Res 1991; 8: 807-814.
24. Merkus FW, et al,. Nasal mucociliary clearance as a factor for nasal drug delivery. Adv Drug Deliv Rev 1998; 29: 13-38. (Pubitemid 28045041)
25. Madsen F, et al,. A rheological examination of the mucoadhesive/mucus interaction: the effect of mucoadhesive type and concentration. J Control Release 1998; 50: 167-178. (Pubitemid 28044111)
26. Bertram U, Bodmeier R,. In situ gelling, bioadhesive nasal inserts for extended drug delivery: in vitro characterization of a new nasal dosage form. Eur J Pharm Sci 2006; 27: 62-71. (Pubitemid 41728256)
27. Piao J, et al,. Development of novel mucoadhesive pellets of metformin hydrochloride. Arch Pharm Res 2009; 32: 391-397.
28. Paterson BM, et al,. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: a proof of concept study. Aliment Pharmacol Ther 2007; 26: 757-766. (Pubitemid 47246202)
29. Sharp PE, La Regina MC,. The Laboratory Rat. Boca Raton, FL: CRC Press, 1998.
30. Eccles R, et al,. Efficacy and safety of an antiviral iota-carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respir Res 2010; 11: 108.
31. Song KH, et al,. Enhanced intestinal absorption of salmon calcitonin (sCT) from proliposomes containing bile salts. J Control Release 2005; 106: 298-308.
32. Kuboyama Y, et al,. Changes in nasal cavity volume and target area of exposure to nasal drops with age in rats. Exp Anim 1996; 45: 15-22. (Pubitemid 126419604)
33. Song KH, et al,. Simple liquid chromatography-electrospray ionization mass spectrometry method for the routine determination of salmon calcitonin in serum. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 775: 247-255.
34. Luessen HL, et al,. Bioadhesive polymers for the peroral delivery of peptide drugs. J Control Release 1994; 29: 329-338. (Pubitemid 24156379)
35. Luessen HL, et al,. Multifunctional polymers for the peroral delivery of peptide drugs. In:, Mathiowitz E, et al., ed. Bioadhesive Drug Delivery Systems. Fundamentals, Novel Approaches, and Development. New York: Marcel Dekker, 1999: 299-339.
36. Illum L,. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002; 7: 1184-1189. (Pubitemid 35430155)
37. Illum L,. Nasal drug delivery-possibilities problems and solutions. J Control Release 2003; 87: 187-198. (Pubitemid 36255456)
38. US Food and Drug Administration. Generally Recognized as Safe (GRAS). [Online] Available at:.
39. Ugwoke MI, et al,. Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. Int J Pharm 2000; 205: 43-51.
40. Murakami T, et al,. Enhanced rectal and nasal absorption of human epidermal growth factor by combined use of the absorption promoter and the synthetic polymer in rats. Eur J Drug Metab Pharmacokinet 1991; Spec 3: 125-131.
41. Drago S, et al,. Gliadin, zonulin and gut permeability: effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. Scand J Gastroenterol 2006; 41: 408-419. (Pubitemid 43675406)
42. Marinaro M, et al,. Zonula occludens toxin acts as an adjuvant through different mucosal routes and induces protective immune responses. Infect Immun 2003; 71: 1897-1902. (Pubitemid 36368721)